A New Look at Leukemia and Lymphoma
Flow cytometric immunophenotyping can assist with the diagnosis of a range of lymphoid and myeloid neoplasms
Flow cytometry is an example of a rapidly evolving IVD technology that is migrating from the highly specialized laboratory to routine clinical testing in the core lab. It has been widely adopted for the assessment of leukemias and lymphomas and is part of the trend toward early detection and monitoring, bringing diagnostics closer to patients. 2017 marked a milestone for the technology when the US Food and Drug Administration (FDA) granted de novo authorization for the in vitro diagnostic use of the first pre-formulated antibody cocktail for leukemia and lymphoma immunophenotyping.
Flow cytometric immunophenotyping evaluates the presence and absence of specific antigens for each individual cell in the specimen. Interpretation of aberrant immunophenotypes requires skill in recognizing the significance of different patterns. As part of the test manufacturer’s available information, a unique case book has been created to aid in this complex pattern recognition. The following case is just one example.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine